GlassScriptPhysician profile
Judith K Weis
NPI 1942252226
$5,298.84
in general payments reported to CMS, 2019-2025
34 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $845 · 2021: $991 · 2022: $816 · 2023: $900 · 2024: $578 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,028.86 | 2021-2025 | Qulipta, Vraylar, Linzess |
| Astrazeneca Pharmaceuticals LP | $571.48 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $485.18 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $223.07 | 2020 | |
| Novo Nordisk INC | $216.47 | 2019-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $201.83 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.58 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Kowa Pharmaceuticals America, INC. | $186.02 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.02 | 2019-2023 | Trintellix |
| Pfizer INC. | $162.62 | 2019-2025 | |
| Astellas Pharma US INC | $156.18 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $155.51 | 2019-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.43 | 2019-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $136.03 | 2019-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $131.39 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $109.30 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $109.07 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $107.51 | 2021-2025 | Repatha, Otezla, Repatha |
| Nestle Healthcare Nutrition INC. | $101.51 | 2022-2023 | |
| Glaxosmithkline, LLC. | $90.10 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $89.66 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.90 | 2022-2023 | |
| Sanofi Pasteur INC. | $76.59 | 2020-2025 | |
| Exact Sciences Corporation | $58.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $49.37 | 2023-2024 | Gemtesa |
| Amarin Pharma, INC. | $49.02 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $44.99 | 2021 | |
| Seqirus USA INC | $41.84 | 2019-2025 | Flucelvax |
| Sunovion Pharmaceuticals INC. | $28.85 | 2021-2022 | |
| Axsome Therapeutics, INC. | $20.98 | 2023 | Sunosi |
| Arbor Pharmaceuticals, INC. | $19.80 | 2020 | |
| Ironshore Pharmaceuticals INC. | $17.70 | 2019 | |
| Optos, INC. | $17.14 | 2020 | |
| Esperion Therapeutics, INC. | $15.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Weis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.